- Home
- NDMO vs KROS Comparison
NDMO vs KROS Comparison
Compare NDMO & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDMO
- KROS
- Stock Information
- Founded
- NDMO 2019
- KROS 2015
- Country
- NDMO United States
- KROS United States
- Employees
- NDMO N/A
- KROS N/A
- Industry
- NDMO Trusts Except Educational Religious and Charitable
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- NDMO Finance
- KROS Health Care
- Exchange
- NDMO Nasdaq
- KROS Nasdaq
- Market Cap
- NDMO 596.2M
- KROS 589.8M
- IPO Year
- NDMO N/A
- KROS 2020
- Fundamental
- Price
- NDMO $10.37
- KROS $11.84
- Analyst Decision
- NDMO
- KROS Buy
- Analyst Count
- NDMO 0
- KROS 11
- Target Price
- NDMO N/A
- KROS $45.33
- AVG Volume (30 Days)
- NDMO 218.6K
- KROS 2.1M
- Earning Date
- NDMO 01-01-0001
- KROS 02-26-2025
- Dividend Yield
- NDMO 6.75%
- KROS N/A
- EPS Growth
- NDMO N/A
- KROS N/A
- EPS
- NDMO N/A
- KROS N/A
- Revenue
- NDMO N/A
- KROS $651,000.00
- Revenue This Year
- NDMO N/A
- KROS $303.27
- Revenue Next Year
- NDMO N/A
- KROS N/A
- P/E Ratio
- NDMO N/A
- KROS N/A
- Revenue Growth
- NDMO N/A
- KROS 8037.50
- 52 Week Low
- NDMO $8.99
- KROS $9.78
- 52 Week High
- NDMO $11.24
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- NDMO 57.30
- KROS 24.87
- Support Level
- NDMO $10.31
- KROS $10.95
- Resistance Level
- NDMO $10.41
- KROS $11.63
- Average True Range (ATR)
- NDMO 0.09
- KROS 0.87
- MACD
- NDMO 0.05
- KROS 1.31
- Stochastic Oscillator
- NDMO 82.29
- KROS 30.60
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.